20 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: BioLineRx, a biopharmaceutical development company, has appointed Dr B J Bormann, to its board of directors. She is currently the CEO of Harbour Antibodies and also the chief business officer of NanoMedical Systems.
Dr Bormann most recently served as senior vice president and global head of therapeutic alliances and strategic partnerships at Boehringer Ingelheim Pharmaceuticals. Prior to that, she held the position of vice president, strategic alliances, at Pfizer.
Dr Bormann earned a BS in biology and chemistry from Fairfield University and received her PhD in biomedical science from the University of Connecticut Health Center in the Department of Pathology. Upon receiving her doctorate, Dr Bormann worked as a research affiliate in the Department of Pathology at the Yale University School of Medicine.
Commenting on the new appointment, Dr Aharon Schwartz, chairman of the board of BioLineRx, said that, "With a career spanning more than two decades at senior executive positions in leading pharmaceutical companies, BJ brings a wealth of industry-tested knowledge, experience, and leadership, making her a valuable addition to our Board. She offers BioLineRx tremendously deep insight and an impressive track record in precipitating partnerships and alliances, as we continue to grow our Company and advance our therapeutic pipeline toward commercialization. On behalf of the entire team at BioLineRx, I am very pleased to welcome BJ to our Board."
Dr Bormann, while speaking about her appointment said that, "I am delighted to join BioLineRx's board of directors. I believe that the company has a very bright future, given its promising therapeutic product pipeline and drug development expertise. I am looking forward to working alongside BioLineRx's experienced management team as they continue to advance the company's pipeline and forge new strategic collaborations within the industry."